Targeting metabolic vulnerabilities downstream of NRF2 activation by glutaminase inhibition offers dual benefits, by inhibiting tumor growth and promoting squamous differentiation, which is consistent with a less invasive phenotype (Figure 6). This evidence concerns the gene GLS and neoplasm.